Response to interferon treatment in essential thrombocythemia with inv(3)(q21q26)

  • Radhika GangarajuEmail author
  • Andrew J. Carroll
  • Josef T. Prchal
Letter to the Editor


Authors’ contributions

RG has taken care of the patient and written the manuscript; AJC was consulted about the chromosomal abnormalities, reviewed material, and edited manuscript; and JTP treated the patient, organized studies, and has written the manuscript.

Funding information

NIH-P01CA108671 (Sub PI: Prchal), Hematology Training grant T32DK007115 (CoPI: Prchal, Fellow: R Gangaraju)

Compliance with ethical standards

Ethical approval

Ethics committee or IRB approval is not required for the publication of this single case report. Details that might disclose the identity of the patient are not included in this manuscript.


  1. 1.
    Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405CrossRefGoogle Scholar
  2. 2.
    Yamazaki H, Suzuki M, Otsuki A et al (2014) A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. Cancer Cell 25:415–427CrossRefGoogle Scholar
  3. 3.
    Pintado T, Ferro MT, San Roman C et al (1985) Clinical correlations of the 3q21;q26 cytogenetic anomaly. A leukemic or myelodysplastic syndrome with preserved or increased platelet production and lack of response to cytotoxic drug therapy. Cancer 55:535–541CrossRefGoogle Scholar
  4. 4.
    Reiter E, Greinix H, Rabitsch W, Keil F, Schwarzinger I, Jaeger U, Lechner K, Worel N, Streubel B, Fonatsch C, Mitterbauer G, Kalhs P (2000) Low curative potential of bone marrow transplantation for highly aggressive acute myelogenous leukemia with inversion inv (3)(q21q26) or homologous translocation t(3;3) (q21;q26). Ann Hematol 79:374–377CrossRefGoogle Scholar
  5. 5.
    Villalon C, Talavera M, Sordo MT et al (2008) Association of inv(3)(q21q26) with essential thrombocythemia in transformation. Cancer Genet Cytogenet 184:122–123CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Hematology-Oncology, Department of MedicineUniversity of Alabama at BirminghamBirminghamUSA
  2. 2.Department of GeneticsUniversity of Alabama at BirminghamBirminghamUSA
  3. 3.Division of Hematology, Department of MedicineUniversity of Utah and Huntsman Cancer InstituteSalt Lake CityUSA

Personalised recommendations